Search Results

You are looking at 71 - 80 of 120 items for :

  • "papillary" x
  • Refine by Access: All x
Clear All
Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

the colon and lung, papillary thyroid cancer, melanoma, and hairy cell leukemia. 8 In BRAF V600E -mutated melanoma, combined BRAF and MEK inhibition has shown superiority to BRAF monotherapy and has proven to be an effective treatment for metastatic

Full access

Lainie Martin and Russell J. Schilder

. Eisen T Boshoff C Mak I . Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer . Br J Cancer 2000 ; 82 : 812 – 817 . 36. Abramson N Stokes PK Luke M . Ovarian and papillary

Full access

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz

, relative to the referent clear-cell histology, both chromophobe (HR, 0.4 at baseline to 0.5 at 96 months of event-free follow-up) and papillary histology (HR, from 0.8 to 0.6, respectively) were stable. Conversely, the CSM hazard was no more significant

Full access

Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini

. 11 Histologic features of OCCC are characterized by solid, papillary, and tubulocystic patterns. 12 Most OCCCs are presumed to arise from endometriotic cysts, 13 and key driver events involving HN-F1B overexpression and somatic ARID1A mutations

Full access

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya, and George Ansstas

melanoma . Cell 2015 ; 161 : 1681 – 1696 . 3. Cancer Genome Atlas Research Network . Integrated genomic characterization of papillary thyroid carcinoma . Cell 2014 ; 159 : 676 – 690 . 4. Landa I Ibrahimpasic T Boucai L

Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

rare, but have been described in cancers of the pancreas, head and neck, esophagus, biliary tract, prostate, colon, and ovaries, as well as in sarcomas and papillary renal cell carcinoma. 12 – 18 Mutations in EGFR are present in rare cases of

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of

Full access

Venkata K. Pokuri, Mihai Merzianu, Shipra Gandhi, Junaid Baqai, Thom R. Loree, and Seema Bhat

, and high-grade papillary urothelial carcinoma of the bladder without muscle invasion 1 year prior, which was treated with transurethral ablation. He was otherwise in good health. Physical examination revealed a 3-cm firm, nontender, immobile mass in

Full access

Richard S. Matulewicz, Brendan T. Frainey, Daniel T. Oberlin, and Joshua J. Meeks

timing of radical cystectomy for BCG failure: comparison of outcomes and risk factors for prognosis . J Urol 2016 ; 195 : 1704 – 1709 . 12. Patriarca C Hurle R Moschini M . Usefulness of pT1 substaging in papillary urothelial bladder

Full access

Therese B. Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E. Calhoun, Mary B. Daly, William B. Farrar, Judy E. Garber, Richard Gray, Caprice C. Greenberg, Rachel Greenup, Nora M. Hansen, Randall E. Harris, Alexandra S. Heerdt, Teresa Helsten, Linda Hodgkiss, Tamarya L. Hoyt, John G. Huff, Lisa Jacobs, Constance Dobbins Lehman, Barbara Monsees, Bethany L. Niell, Catherine C. Parker, Mark Pearlman, Liane Philpotts, Laura B. Shepardson, Mary Lou Smith, Matthew Stein, Lusine Tumyan, Cheryl Williams, Mary Anne Bergman, and Rashmi Kumar

-producing lesions, potential phyllodes tumor, papillary lesions, radial scars, or other histologies of concern to the pathologist. 24 , 29 , 35 , 36 Support for this recommendation includes results of studies showing an underestimation of cancer when atypical